Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
September 18, 2023
Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region
September 7, 2023
Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference
September 6, 2023
Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024
August 10, 2023
Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
August 7, 2023
Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference
August 1, 2023
Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
July 24, 2023
Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023
June 22, 2023
Beyond Air® Secures up to $40 Million Debt Financing
June 15, 2023
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
June 15, 2023

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe